NCT04765137 · Phase 2 · RECRUITING
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
This Phase 2 trial is testing whether atorvastatin, a common cholesterol-lowering drug, can improve how well blood vessels in the brain respond and regulate blood flow in people with mild cognitive impairment. Phase 2 means researchers are exploring whether it works and that it is safe in this group — it is not proven or approved for this purpose yet.
Eligibility criteria
Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors: * MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0. * Memory, processing speed, executive function, language - cognitive scores > 1.5 standard deviations below age-education norms. * Not demented by history. * Not taking statins currently or in the last 6 months. * Cognitive/functional impairment not likely due to another neurological disease or delirium. Exclusion Criteria: * Taking a statin currently or have taken a statin in the last 6 months. * Contraindications to taking a statin. * Transplant patient taking cyclosporine. * Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal). * Diagnosis of dementia by history. * Current diagnosis of substance abuse. * History of stroke or myocardial infarction in past 6 months. * History of HIV.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-08-06